<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818177</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2019001038</org_study_id>
    <nct_id>NCT04818177</nct_id>
  </id_info>
  <brief_title>Immunoglobulin G Therapy Dose Optimization</brief_title>
  <official_title>Optimization of Dosing of Immunoglobulin G in the Obese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of&#xD;
      immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese&#xD;
      patients. There is an ongoing debate regarding the most appropriate dosing of IgG&#xD;
      formulations in obese patients. Obesity poses significant health risks; and evidence&#xD;
      supporting dosing strategies of IgG in obese patients is inadequate. Some of the adverse&#xD;
      reactions have been attributed to a relative overdosing in these patients, due to a limited&#xD;
      distribution of IgG into fat tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The estimated prevalence of overweight and obese individuals &gt;20 years in the US is 154.7&#xD;
      million (nearly double since the early 1960s), and over 1.6 billion people are considered&#xD;
      overweight or obese worldwide. Compounding the health risks associated with obesity is the&#xD;
      insufficient data supporting dosing strategies for a variety of medication used to treat&#xD;
      conditions encountered in obese patients. No consensus on the best dosing strategy for IgG in&#xD;
      obese patients has been established. Total (TBW), ideal (IBW), and adjusted (AdjBW) body&#xD;
      weight-based dosing are being utilized by different institutions. Thus, there is an urgent&#xD;
      need to identify evidence supporting optimal dosing strategies for IgG.&#xD;
&#xD;
      It has been proposed that using TBW to dose IgG in obese patients may increase the risk of&#xD;
      thrombosis owing to increased blood viscosity, activation of platelets, or vasospasm; and the&#xD;
      increase in blood viscosity has been reported as IgG dose dependent. The use of using IBW or&#xD;
      AdjBW has been advocated to reduce the side effect and drug expenditures. It is currently&#xD;
      unknown what the clinical impact is of using measures of body weight other than TBW to&#xD;
      calculate IgG doses, and the effect of obesity on IgG pharmacokinetics has not been&#xD;
      experimentally evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Serum IgG concentrations</measure>
    <time_frame>5 time points (baseline, immediately after dose administration (peak), 2 weeks post dose, just prior to receiving the next scheduled dose (trough))</time_frame>
    <description>A linear mixed effects model to analyze serum IgG concentrations, with normal/obese as the primary predictor but with clinical and demographic variables as covariates.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Normal Weight</arm_group_label>
    <description>Normal weight is defined as BMI 18.5 - 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight or Obese</arm_group_label>
    <description>Overweight or obese is defined as BMI &gt; 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Institutional standard intravenous immune globulin treatment</intervention_name>
    <description>No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight or Obese</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients receiving the institutional standard intravenous immune globulin&#xD;
        therapy. Differences in IgG concentrations will be analyzed between normal weight subjects&#xD;
        (BMI 18.5 - 25 kg/m2) and overweight or obese subjects (BMI &gt; 25 kg/m2).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18 to 75 years&#xD;
&#xD;
          -  currently treated with IVIG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver impairment (elevations in liver enzymes of greater than 3 times the upper limit&#xD;
             of normal)&#xD;
&#xD;
          -  reduced renal function (CrCl &lt; 50 mL/min)&#xD;
&#xD;
          -  Patients with a pacemaker or an automatic implantable cardioverter-defibrillator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Brunetti, Ph D; PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Brunetti, Ph D; PharmD</last_name>
    <phone>7324455215</phone>
    <email>luigi.brunetti@rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine N Yohn, Ph D</last_name>
    <phone>9083284210</phone>
    <email>cy253@pharmacy.rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital Somerset</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Omabegho</last_name>
      <email>marilyn.omabegho@rwjbh.org</email>
    </contact>
    <contact_backup>
      <last_name>Ana Rosa</last_name>
      <email>Ana.Rosa@RWJBH.org</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Brunetti, Ph D; PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Luigi Brunetti, PharmD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Obesity</keyword>
  <keyword>Primary immune deficiency</keyword>
  <keyword>Chronic inflammatory demyelinating polyneuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

